Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer

Cervical cancer is a common malignant tumor in women, and human papillomavirus (HPV) infection is a major cause of cervical cancer. Tumor-infiltrating lymphocytes (TILs) are a heterogeneous group of lymphocytes primarily composed of T lymphocytes found within the tumor parenchyma and stroma. These c...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Zhang, Yong-Min Liu, Dong Li, Shan Liu, Xiao-Jun Cai, Ji-Ying Tang, Zhi-Gang Zuo, Xin-Hui Li, Yi Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1524842/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849310359526047744
author Wei Zhang
Wei Zhang
Yong-Min Liu
Dong Li
Shan Liu
Xiao-Jun Cai
Ji-Ying Tang
Zhi-Gang Zuo
Xin-Hui Li
Yi Zhao
author_facet Wei Zhang
Wei Zhang
Yong-Min Liu
Dong Li
Shan Liu
Xiao-Jun Cai
Ji-Ying Tang
Zhi-Gang Zuo
Xin-Hui Li
Yi Zhao
author_sort Wei Zhang
collection DOAJ
description Cervical cancer is a common malignant tumor in women, and human papillomavirus (HPV) infection is a major cause of cervical cancer. Tumor-infiltrating lymphocytes (TILs) are a heterogeneous group of lymphocytes primarily composed of T lymphocytes found within the tumor parenchyma and stroma. These cells can be isolated from tumor tissue, activated, expanded in vitro, and reinfused into the patient to exert an anti-tumor immune effect. As a form of personalized immunotherapy, TILs therapy has shown satisfactory efficacy and safety in advanced recurrent and metastatic cervical cancer, offering new hope to patients with advanced cervical cancer. However, TILs therapy for advanced cervical cancer still faces several limitations and challenges. This article reviews the process and latest developments in TILs therapy for advanced cervical cancer and discusses the challenges in the usage and prospects for this treatment.
format Article
id doaj-art-38d893a7f3394050b56ffc86776c9cbc
institution Kabale University
issn 1664-3224
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-38d893a7f3394050b56ffc86776c9cbc2025-08-20T03:53:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15248421524842Research progress on tumor-infiltrating lymphocyte therapy for cervical cancerWei Zhang0Wei Zhang1Yong-Min Liu2Dong Li3Shan Liu4Xiao-Jun Cai5Ji-Ying Tang6Zhi-Gang Zuo7Xin-Hui Li8Yi Zhao9Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaInstitute of Clinical Medicine, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, ChinaDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, ChinaCervical cancer is a common malignant tumor in women, and human papillomavirus (HPV) infection is a major cause of cervical cancer. Tumor-infiltrating lymphocytes (TILs) are a heterogeneous group of lymphocytes primarily composed of T lymphocytes found within the tumor parenchyma and stroma. These cells can be isolated from tumor tissue, activated, expanded in vitro, and reinfused into the patient to exert an anti-tumor immune effect. As a form of personalized immunotherapy, TILs therapy has shown satisfactory efficacy and safety in advanced recurrent and metastatic cervical cancer, offering new hope to patients with advanced cervical cancer. However, TILs therapy for advanced cervical cancer still faces several limitations and challenges. This article reviews the process and latest developments in TILs therapy for advanced cervical cancer and discusses the challenges in the usage and prospects for this treatment.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1524842/fullcervical cancertumor-infiltrating lymphocytes (TILs)immunotherapyTILs therapyhuman papillomavirus
spellingShingle Wei Zhang
Wei Zhang
Yong-Min Liu
Dong Li
Shan Liu
Xiao-Jun Cai
Ji-Ying Tang
Zhi-Gang Zuo
Xin-Hui Li
Yi Zhao
Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer
Frontiers in Immunology
cervical cancer
tumor-infiltrating lymphocytes (TILs)
immunotherapy
TILs therapy
human papillomavirus
title Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer
title_full Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer
title_fullStr Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer
title_full_unstemmed Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer
title_short Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer
title_sort research progress on tumor infiltrating lymphocyte therapy for cervical cancer
topic cervical cancer
tumor-infiltrating lymphocytes (TILs)
immunotherapy
TILs therapy
human papillomavirus
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1524842/full
work_keys_str_mv AT weizhang researchprogressontumorinfiltratinglymphocytetherapyforcervicalcancer
AT weizhang researchprogressontumorinfiltratinglymphocytetherapyforcervicalcancer
AT yongminliu researchprogressontumorinfiltratinglymphocytetherapyforcervicalcancer
AT dongli researchprogressontumorinfiltratinglymphocytetherapyforcervicalcancer
AT shanliu researchprogressontumorinfiltratinglymphocytetherapyforcervicalcancer
AT xiaojuncai researchprogressontumorinfiltratinglymphocytetherapyforcervicalcancer
AT jiyingtang researchprogressontumorinfiltratinglymphocytetherapyforcervicalcancer
AT zhigangzuo researchprogressontumorinfiltratinglymphocytetherapyforcervicalcancer
AT xinhuili researchprogressontumorinfiltratinglymphocytetherapyforcervicalcancer
AT yizhao researchprogressontumorinfiltratinglymphocytetherapyforcervicalcancer